MPR

Orladeyo Oral Pellets Approved for Pediatric Hereditary Angioedema

The FDA approval of berotralstat oral pellets offers a new prophylaxis option for children aged 2 years and older with hereditary angioedema.

FDA approves BioCryst's oral pellet formulation of rare disease drug for young children

The U.S. Food and Drug Administration has approved an oral pellet formulation of BioCryst Pharmaceuticals' drug to prevent hereditary angioedema attacks in children aged 2 to under 12, the company ...

How to spot suspicious health supplements and avoid getting scammed

Snopes readers regularly ask whether supplement brands like Neurocept and Burn Peak are legit. Here's how you can tell yourself.

BioCryst wins FDA approval for Orladeyo oral pellets

BioCryst Pharma (BCRX) announced on Friday that the U.S. Food and Drug Administration (FDA) approved an oral pellet ...